Investigating the potential side effects of anti-TNF therapy for rheumatoid arthritis: Cause for concern?

Immunotherapy

Volumn 7, Issue 4, 2015, Pages 353-361

  Atzeni, Fabiola ^a   Gianturco, Luigi ^b   Talotta, Rossella ^c   Varisco, Valentina ^c   Ditto, Maria Chiara ^c   Turiel, Maurizio ^b   Sarzi Puttini, Piercarlo ^c  

^a IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

anti TNF therapy; autoimmunity; cancer; infections; lipid profiles

Indexed keywords

BIOLOGICAL PRODUCT; LIPID; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR;

ATHEROGENESIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BACTERIAL INFECTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CRYPTOCOCCOSIS; DRUG SELECTIVITY; HEART INFARCTION; HERPES ZOSTER; HISTOPLASMOSIS; HUMAN; IMMUNOGENICITY; INFECTION RISK; INFECTIOUS ARTHRITIS; INFUSION RELATED REACTION; INJECTION SITE REACTION; LUPUS LIKE SYNDROME; META ANALYSIS (TOPIC); MYCOBACTERIOSIS; MYCOSIS; NOCARDIOSIS; NON MELANOMA SKIN CANCER; PATIENT MONITORING; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; RISK REDUCTION; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC LUPUS ERYTHEMATOSUS; URINARY TRACT INFECTION; VIRUS INFECTION; ADVERSE EFFECTS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CARDIOVASCULAR DISEASES; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; INFECTION; LIPID METABOLISM; MICROBIOLOGY; PHYSIOLOGIC MONITORING; SKIN; SKIN NEOPLASMS; VIROLOGY;

ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CARDIOVASCULAR DISEASES; HUMANS; IMMUNOTHERAPY; INFECTION; LIPID METABOLISM; MONITORING, PHYSIOLOGIC; SKIN; SKIN NEOPLASMS;

EID: 84928806323     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.15.4     Document Type: Review

References (53)

1. Caporali R, Pallavicini FB, Filippini M et al. Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Autoimmun. Rev. 8, 274-280 (2009).
2. Agarwal SK. Biologic agents in rheumatoid arthritis: an update for managed care professionals. J. Manag. Care Pharm. 17, S14-S18 (2011).
3. Atzeni F, Benucci M, Sallì S, Bongiovanni S, Boccassini L, Sarzi-Puttini P. Different effects of biological drugs in rheumatoid arthritis. Autoimmun. Rev. 12, 575-579 (2013).
4. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls. A population-based study. Arthritis Rheum. 9, 2287-2293 (2002).
5. Horiuchi T, Mitoma H, Harashima S et al. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology 49, 1215-1228 (2010).
6. Harris J, Hope JC, Keane J. Tumor necrosis factor blockers influence macrophage responses to Mycobacterium Tuberculosis. J. Infect. Dis. 198, 1842-1850 (2008).
7. Harris J, Keane J. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin. Exp. Rheum. 161, 1-9 (2010).
8. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat. Clin. Pract. Rheumatol. 2, 602-610 (2006).
9. Keane J, Bresnihan B. Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies. Curr. Opin. Rheumatol. 20, 443-449 (2008).
10. Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford) 53(10), 1872-1885 (2014).
11. Smith MY, Attig B, McNamee L, Eagle T. Tuberculosis screening in prescribers of anti-tumor necrosis factor therapy in the European Union. Int. J. Tuberc. Lung Dis. 16(9), 1168-1173 (2012).
12. Latent tuberculosis infection: a guide for primary health care providers. US Department of Health and Human Services Centers for Disease Control and Prevention National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention (2013). www. cdc. gov/tb/publications
13. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis Infection-USA, 2010; Morbidity and Mortality Weekly Report (2010). www. cdc. gov/mmwr
14. Atzeni F, Benucci M, Sarzi-Puttini P. Infections during treatment with biological agents and possible treatment in clinical practice. Expert Rev. Clin. Immunol. 9, 193-195 (2013).
15. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 54, 2368-2376 (2006).
16. Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor a blockade therapy. Mayo Clin. Proc. 83, 181-189 (2008).
17. Galloway JB, Hyrich KL, Mercer LK et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann. Rheum. Dis. 70(10), 1810-1814 (2011).
18. Davies R, Dixon WG, Watson KD et al. Influence of anti-TNF patient warning regarding avoidance of high risk foods on rates of listeria and salmonella infections in the UK. Ann. Rheum. Dis. 72, 461-462 (2013).
19. Listing J, Strangfeld A, Kary S et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 52, 3403-3412 (2005).
20. Che H, Lukas C, Morel J, Combe B. Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis. Joint Bone Spine 81, 215-221 (2014).
21. Wendling D, Auge B, Bettinger D et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann. Rheum. Dis. 64, 788-789 (2005).
22. Caporali R, Bobbio-Pallavicini F, Atzeni F et al. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res. (Hoboken). 62(6), 749-754 (2010).
23. Cantini F, Boccia S, Goletti D et al. HBV reactivation in patients treated with antitumor necrosis factor-alpha (TNF-) agents for rheumatic and dermatologic conditions: a systematic review and meta-analysis. Int. J. Rheumatol. 2014, 926836 (2014).
24. Vassilopoulos D 1, Calabrese LH. Management of rheumatic disease with comorbid HBV or HCV infection. Nat. Rev. Rheumatol. 8(6), 348-357 (2012).
25. Ji J, Liu X, Sundquist K, Sundquist J. Survival of cancer in patients with rheumatoid arthritis: a follow-up study in Sweden of patients hospitalized with rheumatoid arthritis 1 year before diagnosis of cancer. Rheumatology (Oxford) 50, 1513-1518 (2011).
26. Askling J, Fored CM, Baecklund E, Brandt L et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann. Rheum. Dis. 64, 1414 (2005).
27. Baecklund E, Smedby KE, Sutton LA, Askling J, Rosenquist R. Lymphoma development in patients with autoimmune and inflammatory disorders-what are the driving forces? Semin. Cancer Biol. 24, 61-70 (2014).
28. Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. Br. Med. J. 317, 180-181 (1998).
29. Mariette X, Matucci-Cerinic M, Pavelka K et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis Ann. Rheum. Dis. 70, 1895-1904 (2011).
30. Carmona L, Abasolo L, Descalzo MA et al. BIOBADASER Study Group, EMECAR Study Group. Cancer in patients with rheumatic diseases exposed to TNF antagonists. Semin. Arthritis Rheum. 41, 71-80 (2011).
31. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma inrheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum. 56, 1433-1439 (2007).
32. Lopez-Olivo MA, Tayar JH, MD, Martinez-Lopez JA et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy. a meta-analysis. JAMA 308, 898-908 (2012).
33. Zintzaras E 1, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch. Intern. Med. 165, 2337-2344 (2005).
34. Moulis G, Sommet A, Benè J et al. Cancer risk of anti-TNF- at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses. PLoS ONE 7, e48991 (2012).
35. Atzeni F, Sarzi-Puttini P. Autoantibody production in patients treated with anti-TNF-alpha. Expert Rev. Clin. Immunol. 4, 275-280 (2008).
36. Atzeni F, Talotta R, Salaffi F et al. Immunognicity and autoimmunity during anti-TNF therapy. Autoimmun. Rev. 12, 703-708 (2013).
37. van Schouwenburg PA, van de Stadt LA, de Jong RN. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann. Rheum. Dis. 72(1), 104-109 (2013).
38. Vultaggio A, Matucci A, Nencini F et al. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 65, 657-661 (2010).
39. Benucci M, Saviola G, Meacci F et al. No correlations between the development of specific iga and igm antibodies against anti-TNF blocking agents, disease activity and adverse side reactions in patients with rheumatoid arthritis. Open Rheumatol. J. 7, 75-80 (2013).
40. Ramos-Casals M, Brito-Zeron P, Munoz S et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine 86, 242-251 (2007).
41. Moulis G, Sommet A, Lapeyre-Mestre M et al. Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor A case/non case study in a nationwide pharmacovigilance database. Rheumatology (Oxford) 53, 1864-1871 (2014).
42. Carmona L, Cross M, Williams B, Lassere M, March L. Rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 24, 733-745 (2010).
43. Jacobsson LT 1, Turesson C, Gülfe A et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J. Rheumatol. 32, 1213-1218 (2005).
44. Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res. (Hoboken) 63, 522-529 (2011).
45. Dixon WG, Watson KD, Lunt M et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 56(9), 2905-2912 (2007).
46. Dadoun S, Zeboulon-Ktorza N, Combescure C et al. Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis. Joint Bone Spine 80, 29-33 (2013).
47. Bili A, Tang X, Pranesh S, Bozaite R et al. Tumor necrosis factor inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis. Arthritis Care Res. (Hoboken) 66, 355-363 (2014).
48. Turiel M, Tomasoni L, Sitia S et al. Effects of long-term disease-modifying antirheumatic drugs on endothelial function in patients with early rheumatoid arthritis. Cardiovasc Ther. 28, e53-e64 (2010).
49. Dulai R, Perry M, Twycross-Lewis R, Morrissey D, Atzeni F, Greenwald S. The effect of tumor necrosis factor antagonists on arterial stiffness in rheumatoid arthritis: a literature review. Semin. Arthritis Rheum. 42, 1-8 (2012).
50. Sarzi-Puttini P, Atzeni F, Shoenfeld Y, Ferraccioli G. TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma. Autoimmun. Rev. 4, 153-161 (2005).
51. Daïen CI 1, Duny Y, Barnetche T, Daurès JP, Combe B, Morel J. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann. Rheum. Dis. 71, 862-868 (2012).
52. Ramiro S 1, Gaujoux-Viala C, Nam JL et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann. Rheum. Dis. 73(3), 529-535 (2014).
53. Thalayasingam N 1, Isaacs JD. Anti-TNF therapy. Best Pract. Res. Clin. Rheumatol. 25(4), 549-567 (2011).